Skip to main content

Table 5 Results from HAQ analysis: Mean estimate with 80% credible intervals for each pair-wise comparison

From: The use of continuous data versus binary data in MTC models: A case study in rheumatoid arthritis

Comparison

HAQ

HAQ20

HAQ50

Ada vs P

0.20 (0.17,0.23)*

2.6 (2.2,3.1)*

3.1 (2.1,4.4)*

Inf vs P

0.10 (0.06,0.15)*

1.6 (1.2,2.1)*

2.0 (1.2,3.5)*

Eta vs P

0.31 (0.25,0.37)*

3.6 (2.6,5.2)*

4.1 (2.2,7.7)*

Gol vs P

0.23 (0.17,0.29)*

2.8 (2.0,4.1)*

4.2 (1.9,8.8)*

Cert vs P

0.25 (0.22,0.29)*

3.3 (2.7,4.0)*

5.0 (3.0,7.6)*

Inf vs Ada

-0.10 (-0.15,-0.05)*

0.6 (0.4,0.8)*

0.7 (0.3,1.3)

Eta vs Ada

0.11 (0.04,0.17)*

1.4 (0.9,2.1)

1.3 (0.7,2.7)

Eta vs Inf

0.21 (0.13,0.28)*

2.3 (1.4,3.6)*

2.0 (0.9,4.9)

Gol vs Ada

0.02 (-0.05,0.08)

1.1 (0.7,1.6)

1.4 (0.6,3.3)

Gol vs Inf

0.12 (0.05,0.20)*

1.8 (1.1,2.8)*

2.1 (0.8,5.4)

Gol vs Eta

-0.09 (-0.17,0.00)*

0.8 (0.5,1.3)

1.0 (0.4,2.7)

Cert vs Ada

0.05 (0.00,0.09)*

1.2 (0.97,1.6)

1.6 (0.8,2.8)

Cert vs Inf

0.15 (0.10,0.21)*

2.0 (1.5,2.9)*

2.4 (1.1,4.7)*

Cert vs Eta

-0.06 (-0.13,0.01)

0.9 (0.6,1.3)

1.2 (0.5,2.5)

Cert vs Gol

0.03 (-0.04,0.09)

1.1 (0.8,1.7)

1.2 (0.4,2.7)

σ

0.03 (0.01,0.05)

0.1 (0.0,0.3)

0.4 (0.1,0.6)

  1. Significant results are marked with ∗. Outcome measures are % improvement for continuous HAQ and ORs for HAQ 20 and HAQ 50. Ada=adalimumab; Inf=infliximab; Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo, σ=between trial SD.